Tango Therapeutics (TNGX) Shares Outstanding (Diluted Average) (2021 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Shares Outstanding (Diluted Average) of $143.6 million in Q1 2026, up 23.6% quarter-over-quarter from $116.2 million in Q4 2025, and up 30.17% on a YoY basis from $110.3 million in Q1 2025.
Tango Therapeutics (TNGX) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Tango Therapeutics' Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $143.6 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 30.17% year-over-year to $143.6 million; the TTM figure through Mar 2026 stood at $143.6 million (up 30.17% YoY), while the FY2025 annual figure was $116.2 million, up 6.35% from the prior year.
- Shares Outstanding (Diluted Average) was $143.6 million for Q1 2026 at Tango Therapeutics, up from $116.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $143.6 million in Q1 2026 to a low of $87.7 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $102.2 million across 5 years, with a median of $102.6 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) surged 94.82% in 2022, then gained 0.5% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $87.8 million in 2022, then advanced by 7.69% to $94.6 million in 2023, then gained by 15.5% to $109.2 million in 2024, then gained by 6.35% to $116.2 million in 2025, then advanced by 23.6% to $143.6 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $143.6 million (Q1 2026), $116.2 million (Q4 2025), and $110.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | 143.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143.58 Mn |
| Dec 31, 2025 | 116.17 Mn |
| Jun 30, 2025 | 110.49 Mn |
| Mar 31, 2025 | 110.30 Mn |
| Dec 31, 2024 | 109.23 Mn |
| Sep 30, 2024 | 108.51 Mn |
| Jun 30, 2024 | 108.69 Mn |
| Mar 31, 2024 | 108.17 Mn |
| Dec 31, 2023 | 94.57 Mn |
| Sep 30, 2023 | 97.03 Mn |
| Jun 30, 2023 | 88.28 Mn |
| Mar 31, 2023 | 88.19 Mn |
| Dec 31, 2022 | 87.82 Mn |
| Sep 30, 2022 | 87.87 Mn |
| Jun 30, 2022 | 87.84 Mn |
| Mar 31, 2022 | 87.67 Mn |
| Dec 31, 2021 | 62.11 Mn |
| Sep 30, 2021 | 53.40 Mn |
| Jun 30, 2021 | 45.09 Mn |